All News

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.

Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.

Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.

A float pharmacist reflects on how practicing in different communities revealed that patients often have more in common than they first appear to.

Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss how an investigational meditope-enabled CAR T-cell platform could offer control through adapter dosing and the pharmacist’s role in its clinical development.

A lipidologist outlines how PREVENT, coronary calcium scoring, and restored LDL-C targets guide personalized lipid therapy and where pharmacists fit in.

When even federal guidance sparks debate, an expert advises pharmacists to consider the source and point patients to long-standing healthful eating.

The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss preclinical research on a meditope-enabled platform designed to redirect CAR T cells toward additional tumor targets and support their expansion after infusion.

Panelists explain how health systems can use the National Kidney Foundation’s CKDintercept initiative to build interdisciplinary, value-based kidney care, starting with small patient groups and setting time-bound treatment goals.

The cardiovascular-kidney-metabolic (CKM) framework can replace siloed care with co-management across specialties, centered on an engaged patient and supported by making fuller use of clinical pharmacists.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

The innovation that frees a patient from the infusion chair is the innovation that asks pharmacists to replace, from a distance, everything that chair used to catch.

Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.

In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.

The cardiovascular-kidney-metabolic framework puts the urine albumin-to-creatinine ratio at the center of risk stratification, so that a positive result leads to earlier treatment rather than just being documented.

A panel of 4 health care professionals describe how their health systems adopted the race-free 2021 CKD-EPI equations.

The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.

Two authors of new multidisciplinary consensus recommendations explain how clinical pharmacists speed thrombolytic and reversal agent administration in acute stroke.

A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.

In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.

From red meat to 'big and fluffy' LDL, a lipid expert unpacks fat and cholesterol misconceptions that persist among patients and clinicians.

Pharmacists play a large role in mavacamten care, screening for interacting drugs that can raise exposure and may require dose adjustment or withholding.

In an interview with Pharmacy Times, Paula Rodríguez-Otero, MD, PhD, discusses less frequent linvoseltamab dosing, CRS monitoring, and how community practices could prepare for its potential use in high-risk smoldering multiple myeloma.

Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.